

NCT01794793 Raw comparison:

Summary:
CHIA has 15 criteria while your personal folder has 24 criteria
Total found criteria: 8/15
Total not Found: 7/15
Total Extra: 9
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Patient is currently benefiting from the treatment │ Patient is currently benefiting from the treatment │
│ with pasireotide as determined by the investigator │ with pasireotide as determined by the investigator │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patient has demonstrated compliance as assessed by │ Patient has demonstrated compliance as assessed by │
│ the investigator with the parent study             │ the investigator with the parent study             │
│ requirements                                       │ requirements                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Willingness and ability to comply with scheduled   │ Willingness and ability to comply with scheduled   │
│ visits treatment plans and any other study         │ visits treatment plans and any other study         │
│ procedures                                         │ procedures                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patient has been permanently discontinued from     │ Patient has been permanently discontinued from     │
│ pasireotide study treatment in the parent study    │ pasireotide study treatment in the parent study    │
│ due to unacceptable toxicity non-compliance to     │ due to unacceptable toxicity non-compliance to     │
│ study procedures withdrawal of consent or any      │ study procedures withdrawal of consent or any      │
│ other reason                                       │ other reason                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnant or nursing (lactating) women where        │ Pregnant or nursing (lactating) women where        │
│ pregnancy is defined as the state of a female      │ pregnancy is defined as the state of a female      │
│ after conception and until the termination of      │ after conception and until the termination of      │
│ gestation confirmed by a positive hCG laboratory   │ gestation confirmed by a positive hCG laboratory   │
│ test                                               │ test                                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Total abstinence (when this is in line with the    │ Total abstinence (when this is in line with the    │
│ preferred and usual lifestyle of the subject       │ preferred and usual lifestyle of the patient       │
│ Periodic abstinence (e g calendar ovulation        │ Periodic abstinence (e g calendar ovulation        │
│ symptothermal post-ovulation methods) and          │ symptothermal post-ovulation methods) and          │
│ withdrawal are not acceptable methods of           │ withdrawal are not acceptable methods of           │
│ contraception                                      │ contraception                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Female sterilization (have had surgical bilateral  │ Female sterilization (have had surgical bilateral  │
│ oophorectomy with or without hysterectomy) or      │ oophorectomy with or without hysterectomy) or      │
│ tubal ligation at least six weeks before taking    │ tubal ligation at least six weeks before taking    │
│ study treatment In case of oophorectomy alone only │ study treatment In case of oophorectomy alone only │
│ when the reproductive status of the woman has been │ when the reproductive status of the woman has been │
│ confirmed by follow up hormone level assessment    │ confirmed by follow up hormone level assessment    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Male sterilization (at least 6 months prior to     │ Male sterilization (at least 6 months prior to     │
│ screening) For female subjects on the study the    │ enrolling) For female patients on the study the    │
│ vasectomized male partner should be the sole       │ vasectomized male partner should be the sole       │
│ partner for that subject                           │ partner for that patient                           │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                                  │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Patient is currently participating in a Novartis Oncology sponsored study receiving pasireotide (LAR │
│ and/or s c ) and has fulfilled all required assessments in the parent study (unless the study is     │
│ being terminated) and patients that are benefiting from the study drug have no other alternatives    │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Written informed consent obtained prior to enrolling in roll-over study and receiving study          │
│ medication • If consent cannot be expressed in writing it must be formally documented and witnessed  │
│ ideally via an independent trusted witness                                                           │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patient has participated in a Novartis sponsored combination trial where pasireotide was dispensed   │
│ in combination with another study medication and is still receiving combination therapy (only        │
│ patients receiving pasireotide monotherapy can be included)                                          │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Use of oral injected or implanted hormonal methods of contraception or other forms of hormonal       │
│ contraception that have comparable efficacy (failure rate <1%) for example hormone vaginal ring or   │
│ transdermal hormone contraception                                                                    │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Placement of an intrauterine device (IUD) or intrauterine system (IUS)                               │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Barrier methods of contraception Condom or Occlusive cap diaphragm or cervical/vault caps) with      │
│ spermicidal foam/gel/film/cream/vaginal suppository In case of use of oral contraception women       │
│ should have been stable on the same pill for a minimum of 3 months before taking study treatment     │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Sexually active males unless they use a condom during intercourse while taking drug and for 1 months │
│ after pasireotide s c last dose and 3 months after pasireotide LAR last dose and should not father a │
│ child in this period A condom is required to be used also by vasectomized men in order to prevent    │
│ delivery of the drug via seminal fluid If a study patient or partner becomes pregnant or suspects    │
│ being pregnant during the study or within 1 month after the final dose of pasireotide s c or 3       │
│ months after the final dose of pasireotide LAR the Study Doctor needs to be informed immediately and │
│ ongoing study treatment with pasireotide has to be stopped immediately For patients taking           │
│ pasireotide LAR the future dose injections will be cancelled                                         │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                              │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Use of oral injected or implanted hormonal methods of contraception or placement of an intrauterine  │
│ device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have         │
│ comparable efficacy (failure rate \<1%) for example hormone vaginal ring or transdermal hormone      │
│ contraception                                                                                        │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Women of child-bearing potential defined as all women physiologically capable of becoming pregnant   │
│ unless they are using highly effective methods of contraception during the study treatment and for   │
│ 30 days after the final dose of pasireotide s c and 84 days after the final dose of pasireotide LAR  │
│ Highly effective contraception is defined as either                                                  │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Written informed consent obtained prior to enrolling in roll-over study and receiving study          │
│ medication                                                                                           │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                    │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Women are considered post-menopausal and not of child bearing potential if they have had 12 months   │
│ of natural (spontaneous) amenorrhea with an appropriate clinical profile (i e age appropriate        │
│ history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without          │
│ hysterectomy) total hysterectomy or tubal ligation at least six weeks ago In the case of             │
│ oophorectomy alone only when the reproductive status of the woman has been confirmed by follow up    │
│ hormone level assessment is she considered not of child-bearing potential                            │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ In case of use of oral contraception women should have been stable on the same pill for a minimum of │
│ 3 months before taking study treatment                                                               │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ If consent cannot be expressed in writing it must be formally documented and witnessed ideally via   │
│ an independent trusted witness                                                                       │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patient is currently participating in a Novartis-sponsored study receiving pasireotide (LAR and/or s │
│ c ) on monotherapy or combination therapy (for Cushing's Disease or Acromegaly) and has fulfilled    │
│ all required assessments in the parent study and patients that are benefiting from the study         │
│ treatment have no other alternatives                                                                 │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Sexually active males unless they use a condom during intercourse while taking drug and for 1 months │
│ after pasireotide s c last dose and 3 months after pasireotide LAR last dose should not father a     │
│ child in this period A condom is required to be used also by vasectomized men in order to prevent    │
│ delivery of the drug via seminal fluid                                                               │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛